Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory D Lewis

Showing results (261-270 of 270) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 270 results.
Circulation|November 12, 2025
N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory FitnessJeremy M Robbins, Mark Benson, Anthony R P Verkerke, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
JACC. Heart Failure|December 3, 2025
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection FractionBarry A Borlaug, Julio A Chirinos, Gregory D Lewis, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|January 6, 2026
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyMichael E Nassif, Pablo Garcia-Pavia, Ahmad Masri, et al.
JAMA Cardiology|June 17, 2026
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical TrialGregory D Lewis, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Nature Medicine|June 4, 2024
Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risksAndrew S Perry, Eric Farber-Eger, Tomas Gonzales, et al.
Pageof 27

Showing results (261-270 of 270) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 270 results.
Circulation|November 12, 2025
N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory FitnessJeremy M Robbins, Mark Benson, Anthony R P Verkerke, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
JACC. Heart Failure|December 3, 2025
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection FractionBarry A Borlaug, Julio A Chirinos, Gregory D Lewis, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|January 6, 2026
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyMichael E Nassif, Pablo Garcia-Pavia, Ahmad Masri, et al.
JAMA Cardiology|June 17, 2026
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical TrialGregory D Lewis, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Nature Medicine|June 4, 2024
Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risksAndrew S Perry, Eric Farber-Eger, Tomas Gonzales, et al.
Pageof 27